Probably if they find out there's a cancer that's connected to a certain gene, you get a cool little notification. I guess it's like keeping your genetic information available?
Yes. Some pharmaceutical regimens effectiveness is dependent on patient genome. In other cases, cancer or viral genome. Pharmacogenomics is an emerging field concerned with these things.
The article is paywalled so I didn't read, but sounds like they're pivoting to pharmacogenomics. This field analyzes the genes that code for proteins involved in human drug metabolism. If applied properly it can help narrow down pharmaceutical treatment options. Think of cases where a patient's enzymes may render certain drugs ineffective. If you know a patient is an ultrarapid metabolizer of a given drug, then maybe you don't need to waste everyone's time trialing it.
How they schemed to create a perpetual revenue stream from this, I can only guess. My brain doesn't work like theirs.
I had no idea they were running a prescription mill lmao
What is the plan there, harvest people's biological data and prescribe them drugs? No one is buying the service more than once right?
They’re likely selling that information to insurance companies, law enforcement, military, pharma, etc.
They locked the most useful analysis and results from a one off test behind an expensive subscription model.
What's included in that subscription
Hexbear Pro account, I'm hearing.
Probably if they find out there's a cancer that's connected to a certain gene, you get a cool little notification. I guess it's like keeping your genetic information available?
Yes. Some pharmaceutical regimens effectiveness is dependent on patient genome. In other cases, cancer or viral genome. Pharmacogenomics is an emerging field concerned with these things.
I love to pay a subscription for something I will only use one time, great business model!
The article is paywalled so I didn't read, but sounds like they're pivoting to pharmacogenomics. This field analyzes the genes that code for proteins involved in human drug metabolism. If applied properly it can help narrow down pharmaceutical treatment options. Think of cases where a patient's enzymes may render certain drugs ineffective. If you know a patient is an ultrarapid metabolizer of a given drug, then maybe you don't need to waste everyone's time trialing it.
How they schemed to create a perpetual revenue stream from this, I can only guess. My brain doesn't work like theirs.
Probably get more investor money until they're able to find a way to squeeze cash out of that data. Sounds like that plan is falling flat, though.